




Searching News Database: PARP inhibitor
HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
HSMN NewsFeed - 30 Mar 2017
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Additional items found! 3

Members Archive contains
3 additional stories matching:
PARP inhibitor
(Password required)
PARP inhibitor
(Password required)